These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 27414516)

  • 1. Hydroxyl radical production by the iron complex of the hydrolysis product of the antioxidant cardioprotective agent ICRF-187 (dexrazoxane).
    Malisza KL; Hasinoff BB
    Redox Rep; 1996 Feb; 2(1):69-73. PubMed ID: 27414516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
    Malisza KL; Hasinoff BB
    Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane).
    Hasinoff BB
    Free Radic Res; 1995 Apr; 22(4):319-25. PubMed ID: 7633562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemistry of dexrazoxane and analogues.
    Hasinoff BB
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction.
    Thomas C; Vile GF; Winterbourn CC
    Biochem Pharmacol; 1993 May; 45(10):1967-72. PubMed ID: 8390256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187).
    Buss JL; Hasinoff BB
    Arch Biochem Biophys; 1995 Feb; 317(1):121-7. PubMed ID: 7872773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scavenging effects of dexrazoxane on free radicals.
    Junjing Z; Yan Z; Baolu Z
    J Clin Biochem Nutr; 2010 Nov; 47(3):238-45. PubMed ID: 21103033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fe-EDTA-Bisamide and Fe-ADR-925, The Iron-Bound Hydrolysis Product of the Cardioprotective Agent Dexrazoxane, Cleave DNA Via the Hydroxyl Radical.
    Magliery TJ; Vitellaro LK; Diop NK; Marusak RA
    Met Based Drugs; 1997; 4(4):199-205. PubMed ID: 18475789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
    Schroeder PE; Wang GQ; Burczynski FJ; Hasinoff BB
    Drug Metab Dispos; 2005 Jun; 33(6):719-25. PubMed ID: 15764716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
    Schroeder PE; Hasinoff BB
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925.
    Hasinoff BB; Kala SV
    Agents Actions; 1993 May; 39(1-2):72-81. PubMed ID: 8285144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187).
    Schroeder PE; Davidson JN; Hasinoff BB
    Drug Metab Dispos; 2002 Dec; 30(12):1431-5. PubMed ID: 12433815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
    Hasinoff BB; Schroeder PE; Patel D
    Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.
    Buss JL; Hasinoff BB
    Agents Actions; 1993 Sep; 40(1-2):86-95. PubMed ID: 8147274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
    Hasinoff BB
    Cardiovasc Toxicol; 2002; 2(2):111-8. PubMed ID: 12271154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
    Wu X; Patel D; Hasinoff BB
    J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
    Schroeder PE; Hasinoff BB
    Drug Metab Dispos; 2005 Sep; 33(9):1367-72. PubMed ID: 15980099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane.
    Hasinoff BB; Tran KT
    J Inorg Biochem; 1999; 77(3-4):257-9. PubMed ID: 10643663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system.
    Malisza KL; Hasinoff BB
    Arch Biochem Biophys; 1995 Aug; 321(1):51-60. PubMed ID: 7639535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity.
    Diop NK; Vitellaro LK; Arnold P; Shang M; Marusak RA
    J Inorg Biochem; 2000 Feb; 78(3):209-16. PubMed ID: 10805177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.